By Nick Paul Taylor
Aviptadil has gone 0 for 2 on emergency use authorization filings at the FDA. The new rejection is the latest in a series of blows to the COVID-19 candidate, driving NRx Pharmaceuticals to shift focus to its bipolar depression prospect.
read more
By Paige Minemyer
At UnitedHealthcare, the scale and reach of the country's largest private insurer enable investments and initiatives that serve as a critical backbone to its relationship with members, said Andrew Billioux, M.D., vice president of social determinants of health at UHC.
read more
By Andrea Park
As the opioid epidemic rages on, healthcare providers and scientists are still searching for a less addictive alternative to the drugs for pain relief.
read more
By Angus Liu
Novartis is buying a pass to expedite FDA review for a future drug application. For $100 million, the Swiss pharma is acquiring a priority review voucher from opioid crisis-crippled Mallinckrodt.
read more
By Julie Appleby, Kaiser Health News
New government rules force health insurers to publicly disclose what they pay for just about every service. That information could help consumers and employers know whether they’re getting a fair deal.
read more
By Nick Paul Taylor
Akebia Therapeutics has extracted one final payday from Otsuka Pharmaceutical. With Otsuka cutting its ties to oral anemia drug vadadustat in the wake of rejection by the FDA, Akebia has secured a $55 million settlement, sending its bargain basement share price up 50% in after-hours trading.
read more
By Andrea Park
Medtronic is now the proud owner of a handful of left-heart access devices, designed to help surgeons make the journey from the right atrium of the heart to the left in procedures for left-atrial appendage closure, mitral valve repair, atrial fibrillation ablation and more.
read more
By Heather Landi
Healthcare providers are not permitted to disclose patient health information unless faced with a court order, including information relating to abortion and other sexual and reproductive health care, HHS said Wednesday.
read more
By Annalee Armstrong
Just when biotechs could use cash the most, the well has dried up. Venture financing deal value for U.S.-based biotechs fell by 46% in the first quarter, compared to the same period a year ago, according to GlobalData.
read more
By Kevin Dunleavy
Oxford Biomedica has revealed an extension of its contract with AstraZeneca to produce COVID-19 vaccines through 2025, but only on an “as needed basis,” the company said. This comes just nine months after Oxford announced a $68 million investment from the over-strapped Serum Institute of India to increase its ability to manufacture vaccines for AZ at its Oxbox facility.
read more
By Conor Hale
No more squeezing: The FDA has cleared a smartwatch-like blood pressure device that foregoes the need for an inflatable cuff.
read more
